Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 229 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... December 19, 2023 Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... July 5, 2024 Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers January 21, 2022 Advances in Treating Kidney Cancer and Metastatic Prostate Cancer: Research from... January 25, 2024 Load more HOT NEWS Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... EMA Recommends Extension of Indications for Sugemalimab Forging Military Partnerships to Empower the Cancer Research Enterprise The link between Down syndrome and childhood leukaemia
